Mithra and Lotus announce approval of ALYSSA®, an innovative oral contraceptive, in both Taiwan and Hong Kong

,

21 September 2022, 7:30 CEST – Taipei City, Taiwan and Liege, Belgium Lotus Pharmaceutical Co., Ltd. (TWSE: 1795, “Lotus”) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, “Mithra”) today are pleased to announce that Estelle®, the first-of-its-kind oral contraceptive with a novel estrogen developed by Mithra, has been approved by both Taiwan Food and Drug Administration (TFDA) and Hong Kong Drug Office, Department of Health, under the trademark ALYSSA®. Through this partnership with Mithra, Lotus will be exclusively marketing the product in Taiwan and Hong Kong.